CD5 and T-cell non-Hodgkin lymphoma: Additional challenges with autologous CD5 CAR-T manufacturing for T cell lymphoma include malignant cell contamination, as observed in a study from Hill et al., in which a CAR-T product had to be abandoned before infusion, as well as the potential for a long interval from apheresis to CAR-T cell infusion, with two patients dying from disease progression in this study while awaiting receipt of CAR-T cells [133].